This review summarizes recent advances in m6A-targeted cancer therapy, with emphasis on small-molecule inhibitors and RNA-based strategies targeting m6A regulators, and highlights their integration with nanocarriers to improve drug stability, pharmacokinetic properties, tumor accumulation, and therapeutic selectivity.
Chen-Yu Li, Yuan Guo, Wen-Jun Jiang et al.· International Journal of Nan...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.